维泊妥珠单抗治疗弥漫大B细胞淋巴瘤的治疗进展

Research Progress of Polatuzumab Vedotin in the Treatment of Diffuse Large B-Cell Lymphoma

摘要: 弥漫大B细胞淋巴瘤(DLBCL)是最常见非霍奇金淋巴瘤(NHL)亚型。目前利妥昔单抗联合CHOP方案化疗为DLBCL患者的一线治疗方案，但目前仍有约30%~40%患者可能出现难治或复发。维泊妥珠单抗是首个获批的CD79bADC药物，其联合化疗方案可治疗初治或复发/难治性DLBCL患者，可显著延长患者的生存期，且耐受性良好。维泊妥珠单抗联合化疗治疗DLBCL常见的不良反应包括输注相关反应(IRR)、血细胞减少、周围神经病等。笔者拟就维泊妥珠单抗治疗DLBCL的作用机制、用药方案、临床疗效及不良反应等最新研究进展进行综述，旨在为维泊妥珠单抗临床治疗DLBCL患者提供参考。

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma (NHL). At present, rituximab combined with CHOP chemotherapy is the first-line treatment for DLBCL patients, but at present, about 30%~40% of patients may be refractory or relapse. Po-latuzumab vedotin is the first approved CD79bADC drug to be treated with a combination chemo-therapy regimen that significantly extends survival and is well tolerated in initially treated or re-lapsed/refractory DLBCL patients. Common adverse reactions of polatuzumab vedotin combined with chemotherapy for DLBCL include infusion related reactions (IRR), hemocytopenia, peripheral neuropathy, etc. The author intends to review the latest research progress on the mechanism of ac-tion, medication regimen, clinical efficacy and adverse reactions of polatuzumab vedotin in the treatment of DLBCL, in order to provide reference for the clinical treatment of polatuzumab vedotin in patients with DLBCL.